Bharat Biotech to develop intranasal Vaccine for Covid-19
Bharat Biotech along with virologists of University of Wisconsin and Madison have begun development and testing of a new vaccine called CoroFlu for COVID-19.
The vaccine is to be developed with the M2SR vaccine as the main component. The M2SR vaccine is used against flu. The M2SR is a self-limiting version of the influenza virus. It induces immune response against flu.
The gene sequences of SARS-CoV-2 that causes the COVID-19 disease is to be inserted into the M2SR. This will induce immunity against corona virus. The process is expected to take three to six months. The vaccine will be delivered intranasally.
The Bharat Biotech is to manufacture around 300 million doses of the vaccine. The doses are to be distributed all over the world.
Bharat Biotech is an Indian Biotechnology company. It is headquartered at Hyderabad. It was founded by Krishna Ella, an Indian Scientist. It is the first bio-pharma company audited and approved by the Korean Food and Drugs Administration, Hyderabad.
Category: Science & Technology Current Affairs